Predicting the nature of pleural effusion in patients with lung adenocarcinoma based on 18F-FDG PET/CT

EJNMMI Research

Table 2 Univariate and multivariate logistic regression analyses for the diagnosis of MPE in the training cohort

Variables	Univariate analysis			Multivariate analysis
Variables	P value	OR	95% CI	P value	OR	95% CI
Abnormal serum CEA levels	< 0.001*	8.988	4.694–17.211	< 0.001*	11.315	3.456–37.042
SUVmax of prime tumor	0.013*	1.064	1.013–1.117	0.082	0.892	0.785–1.014
Tumor attachment to the pleura	< 0.001*	8.452	4.898–14.587	0.491	2.184	0.236–20.219
Tumor with SUVmax ≥ 2.5 and attachment to the pleura	< 0.001*	27.600	14.276–53.359	0.007*	19.729	2.226–174.862
Obstructive atelectasis or pneumonia	< 0.001*	5.643	3.037–10.485	< 0.001*	12.185	3.253–45.648
Pleural thickening ≥ 3 mm	0.007*	2.206	1.235–3.939	0.901	1.159	0.114–11.790
Pleural thickening ≥ 10 mm	0.036*	1.697	1.036–2.782	0.214	0.176	0.011–2.720
Diffuse irregular pleural thickening	0.004*	2.360	1.312–4.247	0.600	3.270	0.039–275.721
SUVmax of pleura	< 0.001*	1.929	1.571–2.370	< 0.001*	2.510	1.547–4.073
Pleural thickening ≥ 3 mm with SUVmax ≥ 2.5	< 0.001*	4.006	2.419–6.634	0.851	1.309	0.078–21.930
Pleural thickening ≥ 10 mm with SUVmax ≥ 2.5	< 0.001*	3.296	2.019–5.382	0.581	2.648	0.083–84.110
Focal pleural thickening ≥ 10 mm with SUVmax ≥ 2.5	0.001*	2.665	1.502–4.731	0.909	1.142	0.119–10.953
Diffuse irregular pleural thickening with SUVmax ≥ 2.5	0.001*	2.735	1.472–5.083	0.633	0.297	0.002–43.162
CT attenuation value of pleural effusion	0.004*	1.073	1.022–1.127	0.171	1.077	0.968–1.198
SUVmax of pleural effusion	< 0.001*	15.488	7.143–33.583	< 0.001*	35.305	8.345–149.374
SUVmax of hilar or mediastinal lymph node	0.034*	1.064	1.005–1.127	0.972	0.998	0.883–1.128